These observations raise the possibility that treatments targeting TRH expression, the receptor for this biologically active peptide, or related signaling molecules, could be useful in treating or preventing L-DOPA-induced dyskinesias in human PD. The gene discussed is TRH; the disease is drug-induced dyskinesia.